The ibogaine medical subculture

被引:114
作者
Alper, Kenneth R. [1 ,2 ]
Lotsof, Howard S. [3 ]
Kaplan, Charles D. [4 ]
机构
[1] NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Neurol, New York, NY 10016 USA
[3] Dora Weiner Fdn, Staten Isl, NY 10301 USA
[4] Maastricht Uni, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands
关键词
ibogaine; iboga alkaloid; substance-related disorders; opioid-related disorders; substance withdrawal; medical ethnography;
D O I
10.1016/j.jep.2007.08.034
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Aim of the study: Ibogaine is a naturally occurring psychoactive indole alkaloid that is used to treat substance-related disorders in a global medical subculture, and is of interest as an ethnopharmacological prototype for experimental investigation and possible rational pharmaceutical development. The subculture is also significant for risks due to the lack of clinical and pharmaceutical standards. This study describes the ibogaine medical subculture and presents quantitative data regarding treatment and the purpose for which individuals have taken ibogaine. Materials and methods: All identified ibogaine "scenes" (defined as a provider in an associated setting) apart from the Bwiti religion in Africa were studied with intensive interviewing, review of the grey literature including the Internet, and the systematic collection of quantitative data. Results: Analysis of ethnographic data yielded a typology of ibogaine scenes, "medical model", "lay provider/treatment guide", "activist/self-help", and "religious/spiritual". An estimated 3414 individuals had taken ibogaine as of February 2006, a fourfold increase relative to 5 years earlier, with 68% of the total having taken it for the treatment of a substance-related disorder, and 53% specifically for opioid withdrawal. Conclusions: Opioid withdrawal is the most common reason for which individuals took ibogaine. The focus on opioid withdrawal in the ibogaine subculture distinguishes ibogaine from other agents commonly termed "psychedelics", and is consistent with experimental research and case series evidence indicating a significant pharmacologically mediated effect of ibogaine in opioid withdrawal. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:9 / 24
页数:16
相关论文
共 147 条
  • [1] Aceto M D, 1992, NIDA Res Monogr, V119, P513
  • [2] Alper K R, 2001, Alkaloids Chem Biol, V56, P249, DOI 10.1016/S0099-9598(01)56018-6
  • [3] Alper K R, 2001, Alkaloids Chem Biol, V56, P1, DOI 10.1016/S0099-9598(01)56005-8
  • [4] Alper KR, 1999, AM J ADDICTION, V8, P234
  • [5] Methadone at tapered doses for the management of opioid withdrawal
    Amato, L
    Davoli, M
    Minozzi, S
    Ali, R
    Ferri, M
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03):
  • [6] [Anonymous], 2007, Increases in methadone-related deaths: 1999-2004
  • [7] Modulation of morphine-induced antinociception by ibogaine and noribogaine
    Bagal, AA
    Hough, LB
    Nalwalk, JW
    Glick, SD
    [J]. BRAIN RESEARCH, 1996, 741 (1-2) : 258 - 262
  • [8] Bailey K.D., 1994, QUANTITATIVE APPL SO, P7
  • [9] THE ALKALOIDS OF TABERNANTHE-IBOGA .4. THE STRUCTURES OF IBOGAMINE, IBOGAINE, TABERNANTHINE AND VOACANGINE
    BARTLETT, MF
    DICKEL, DF
    TAYLOR, WI
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1958, 80 (01) : 126 - 136
  • [10] BASTIAANS E, 2004, THESIS VRIJE U AMSTR